The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2025Assessment of Artificial Intelligence (AI) and Blood-Brain Barrier Technology
Study Rationale: Companies are currently using artificial intelligence (AI) to design and develop new drugs and developing new ways to get drugs across the protective blood-brain barrier (BBB) and...
-
Biomarkers to Support Therapeutic Trials Program, 2025Ultra-sensitive Quantification of Phosphorylated LRRK2 in Biofluids from Clinical Trials of Therapeutic Candidates
Study Rationale: LRRK2 is a protein for which inappropriate activation is associated with Parkinson’s disease (PD). Investigators are therefore pursuing the activity of LRRK2 as a potential...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Elucidating the Role of PINK1 and PRKN in Cell Type-specific Responses to Alpha-synuclein Pathology
Study Rationale: Parkinson’s disease (PD) is associated with loss of dopamine neurons and aggregation of the protein alpha-synuclein. Mutations that impair the function of PINK1 and PRKN, proteins...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Accelerating Biological Understanding and Therapeutic Translation for PD-Biology
Study Rationale: Mutations in the PINK1 and Parkin genes cause early-onset Parkinson’s disease (PD). In rats with similar mutations in PINK1 and Parkin, we observed pronounced degeneration of nerve...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Identifying Biochemical, Histological and Molecular Signatures of Constipation Associated with Parkinson’s Disease
Study Rationale: Constipation is one of the most common non-motor symptoms of Parkinson’s disease (PD). It occurs in 50 to 80 percent of people with PD and doubles the risk of PD diagnosis after 10...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Studying SCAMPs: Membrane Proteins that Control Trafficking of Alpha-synuclein
Study Rationale: Parkinson’s disease (PD) progresses with the death of nerve cells in the brain. Some forms of the disease run in families due to mutations in important genes. One of these genes...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.